Intellectual Property

Neuronascent has submitted a number of provisional, PCT and National patent applications for the composition and use of families of structures that promote neurogenesis and neuron regeneration as therapeutics for neurodegenerative and psychiatric disorders.

National patent filing on lead families, both Composition and Use

  • March 2008 filed North America, Asia, Europe and Australia
  • Issued by USPTO & Russia in 2011, S. Korea and China (limited claims) 2012, Australia and Canada 2013, Japan and Israel 2014, Second USPTO 2015
  • Lead AD/PD (NNI-362) and neuropsychiatric (NNI-351) therapies covered

National Patent filing on second family, both Composition and Use (NNI-370-PD)

  • December 2009 filed in North America, Asia, Europe and Australia
  • Claims issued by USPTO, Japan and EU covering neurodegenerative disease reversing agent

National Patent Filing - Down Syndrome

  • Filed 2010, PCT published, Issued AUS, CN, JP, and RU, others pending
  • Use and pharmaceutical composition patent for lead families

 


  » Home
» News & Events
» Contact Us
ABOUT US
Management Team
Directors & Advisors
Collaborators
Memberships
TECHNOLOGY
Neurogenesis & Neuron Regeneration
Drug Discovery
Intellectual Property
R&D PROGRAMS
Alzheimer's Disease
Depression
Parkinson's Disease
Down Syndrome
Ischemia
Hibernation and Ischemia
  © 2016 NeuroNascent, Inc. - All Rights Reserved
This website contains forward-looking statements, which are made pursuant to the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. Forward-looking statements are commonly identified by words such as “would,” “may,” “will,” “expects,” and other terms with similar meaning. Forward-looking statements are based on current beliefs, assumptions and expectations and speak only as of the date of this site and involve risks and uncertainties that could cause actual results to differ materially from current expectations.